PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2020-02-04
Target enrollment:
Participant gender:
Summary
This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913
can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor
stem cell transplant.